The estimated Net Worth of Steven N. Gordon is at least $805 Mille dollars as of 8 August 2017. Steven Gordon owns over 1,000 units of Kadmon Inc stock worth over $804,850 and over the last 8 years Steven sold KDMN stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Steven Gordon KDMN stock SEC Form 4 insiders trading
Steven has made over 1 trades of the Kadmon Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Steven bought 1,000 units of KDMN stock worth $2,470 on 8 August 2017.
The largest trade Steven's ever made was buying 1,000 units of Kadmon Inc stock on 8 August 2017 worth over $2,470. On average, Steven trades about 143 units every 0 days since 2016. As of 8 August 2017 Steven still owns at least 84,721 units of Kadmon Inc stock.
You can see the complete history of Steven Gordon stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Steven Gordon's mailing address?
Steven's mailing address filed with the SEC is C/O KADMON HOLDINGS, INC., 450 E. 29TH STREET, NEW YORK, NY, 10016.
Insiders trading at Kadmon Inc
Over the last 8 years, insiders at Kadmon Inc have traded over $7,020,661 worth of Kadmon Inc stock and bought 7,084,916 units worth $54,943,934 . The most active insiders traders include Advisors Llcperceptive Life..., Asset Management Lp Golden ... e Daniel S Third Point Llc Loeb. On average, Kadmon Inc executives and independent directors trade stock every 29 days with the average trade being worth of $1,948,175. The most recent stock trade was executed by Harlan Waksal on 13 March 2020, trading 16,000 units of KDMN stock currently worth $46,880.
What does Kadmon Inc do?
Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.
What does Kadmon Inc's logo look like?
Complete history of Steven Gordon stock trades at Kadmon Inc
Kadmon Inc executives and stock owners
Kadmon Inc executives and other stock owners filed with the SEC include:
-
Harlan Waksal,
President, Chief Executive Officer, Director -
Steven Meehan,
Chief Financial Officer, Executive Vice President -
Gregory Moss,
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary -
Dr. Harlan W. Waksal,
Pres, CEO & Director -
Gregory S. Moss Esq.,
Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer -
Arthur Kirsch,
Independent Director -
David Cohen,
Independent Director -
Cynthia Schwalm,
Independent Director -
Eugene Bauer,
Independent Director -
Tasos Konidaris,
Non-Executive Independent Chairman of the Board -
Ellen Cavaleri,
IR Contact Officer -
Nancy Miller-Rich,
Director -
John Ryan,
Executive Vice President, Chief Medical Officer -
Dr. Simon Cooper,
Sr. VP & Chief Medical Officer -
Haya Taitel M.S., R.Ph.,
Sr. VP & Chief Commercial Officer -
Sanjay Aggarwal,
Sr. VP of Clinical Devel. -
Kyle Carver,
Sr. VP, Chief Accounting Officer & Controller -
Charles Darder,
Principle Accounting Officer -
Asset Management Lp Golden ...,
-
D. Dixon Boardman,
-
Konstantin Poukalov,
EVP, Chief Financial Officer -
Alexandria Forbes,
-
Andrew B Cohen,
-
I, Llc Kadmon,
-
Susan Wiviott,
-
Shengda Zan,
-
Thomas E Shenk,
-
Steven N. Gordon,
Exec VP, GC, Chief Admin, Comp -
Lawrence Kenneth Cohen,
Exec. VP, Business Develop. -
Daniel S Third Point Llc Loeb,
-
Bart M Schwartz,
-
Advisors Llcperceptive Life...,
-
Kyle Carver,
SVP, CAO, Controller -
Cynthia Louise Flowers,
Director